دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Tortoise (Endoscopy-Driven Treatment) and the Hare (Prophylactic Treatment): Who Wins the Race to Beat Post-Operative Recurrence of Crohn’s Disease?
Lakshman Kumar, Glen Doherty
doi : 10.1093/ecco-jcc/jjac165
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 309–310
Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn’s and Colitis Organisation [ECCO] Position Paper
Jurij Hanzel, Peter Bossuyt, Valerie Pittet, Mark Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Johan Burisch, Salvatore Leone, Roberto Saldaña, Filip Baert, Uri Kopylov, Susanna Jäghult, Michel Adamina, Naila Arebi, Krisztina Gecse
doi : 10.1093/ecco-jcc/jjac136
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 311–317
The utility of real-world data is dependent on the quality and homogeneity of reporting. We aimed to develop a core outcome set for real-world studies in adult patients with inflammatory bowel disease [IBD].
Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn’s Disease
Vincent Joustra, Joris van Sabben, Eline van der does de Willebois, Marjolijn Duijvestein, Nanne de Boer, Jeroen Jansen, Jarmila van der Bilt, Wytze Lameris, Willem Bemelman, Christianne Buskens, Geert D’Haens
doi : 10.1093/ecco-jcc/jjac139
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 318–328
Whereas immediate postoperative treatment has shown effectiveness in reducing endoscopic postoperative recurrence [POR], evidence regarding the clinical benefit is limited. We compared rates of clinical POR in Crohn’s disease [CD] patients receiving immediate prophylactic treatment with rates in patients receiving endoscopy-driven treatment.
Disease Activity Patterns of Inflammatory Bowel Disease—A Danish Nationwide Cohort Study 1995–2018
Mads Damsgaard Wewer, Ebbe Langholz, Pia Munkholm, Flemming Bendtsen, Jakob Benedict Seidelin, Johan Burisch
doi : 10.1093/ecco-jcc/jjac140
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 329–337
Few studies have assessed the contemporary patterns of disease activity in patients with inflammatory bowel disease [IBD]. We aimed to describe the disease patterns and their long-term outcomes.
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme
William J Sandborn, Geert R D’Haens, Bruce E Sands, Remo Panaccione, Siew C Ng, Nervin Lawendy, Nicole Kulisek, Irene Modesto, Xiang Guo, Rajiv Mundayat, Chinyu Su, Ivana Vranic, Julian Panés
doi : 10.1093/ecco-jcc/jjac141
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 338–351
Tofacitinib is an oral small molecule Janus kinase [JAK] inhibitor for the treatment of ulcerative colitis. We report an integrated summary of tofacitinib safety [exposure: ≤7.8 years] from the global clinical programme.
Epidemiology, Treatment Strategy, Natural Disease Course and Surgical Outcomes of Patients with Ulcerative Colitis in Western Hungary – A Population-based Study Between 2007 and 2018: Data from the Veszprem County Cohort
Zsuzsanna Kurti, Lorant Gonczi, Laszlo Lakatos, Petra A Golovics, Tunde Pandur, Gyula David, Zsuzsanna Erdelyi, Istvan Szita, Peter L Lakatos
doi : 10.1093/ecco-jcc/jjac142
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 352–360
The number of population-based studies in ulcerative colitis [UC] from Eastern Europe is limited. Our aim here was to analyse the incidence, prevalence, disease phenotype, treatment strategy, disease course and colectomy rates in a prospective population-based inception cohort including UC patients diagnosed between 2007 and 2018. The present study is a continuation of the Veszprem IBD cohort since 1977.
Perianal Crohn’s Disease and the Development of Colorectal and Anal Cancer: A Systematic Review and Meta-analysis
Martha Pollen Johansen, Mads Damsgaard Wewer, Andreas Nordholm-Carstensen, Johan Burisch
doi : 10.1093/ecco-jcc/jjac143
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 361–368
The aim of this systematic review was to assess the literature on the incidence and risk factors for colorectal cancer and anal cancer in patients with perianal Crohn’s disease.
Darvadstrocel for Complex Perianal Fistulas in Japanese Adults with Crohn’s Disease: A Phase 3 Study
Satomi Furukawa, Tsunekazu Mizushima, Ryo Nakaya, Mari Shibata, Takayoshi Yamaguchi, Kenji Watanabe, Kitaro Futami
doi : 10.1093/ecco-jcc/jjac144
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 369–378
Previous studies conducted in Europe suggested that darvadstrocel, a suspension of expanded, allogeneic, adipose-derived, mesenchymal stem cells, is safe and effective for treatment-refractory complex perianal fistulas in patients with Crohn’s disease.
What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study
Elise Schoefs, Séverine Vermeire, Marc Ferrante, João Sabino, Tessy Lambrechts, Luisa Avedano, Isabella Haaf, Maria Stella De Rocchis, Andrea Broggi, Magdalena Sajak-Szczerba, Roberto Saldaña, Rosanne Janssens, Isabelle Huys
doi : 10.1093/ecco-jcc/jjac145
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 379–388
As more therapeutic options with their own characteristics become available for inflammatory bowel disease [IBD], drug development and individual treatment decision-making needs to be tailored towards patients’ preferences and needs. This study aimed to understand patient preferences among IBD patients, and their most important treatment outcomes and unmet needs.
Interobserver Reliability of the Nancy Index for Ulcerative Colitis: An Assessment of the Practicability and Ease of Use in a Single-Centre Real-World Setting
Huy Duc Le, Theresa Pflaum, Johannes Labrenz, Soner Sari, Fabienne Bretschneider, Florian Tran, Arne Lassen, Susanna Nikolaus, Silke Szymczak, Diana Kormilez, Philip Rosenstiel, Stefan Schreiber, Konrad Aden, Christoph Röcken
doi : 10.1093/ecco-jcc/jjac146
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 389–395
Histological disease severity assessment in ulcerative colitis [UC] has become a mainstay in the definition of clinical endpoints [‘histological remission’] in clinical trials of UC.
Surgical Intervention is Effective for the Treatment of Crohn’s-related Rectovaginal Fistulas: Experience From a Tertiary Inflammatory Bowel Disease Practice
Ana M Otero-Piñeiro, Xue Jia, Karina E Pedersen, Tracy Hull, Jeremy Lipman, Stefan Holubar, Scott R Steele, Amy L Lightner
doi : 10.1093/ecco-jcc/jjac151
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 396–403
Rectovaginal fistula occurs in up to 10–20% of women with Crohn’s disease, significantly affecting their quality of life. We sought to determine outcomes of single and repeat operative interventions.
Most Placebo-Controlled Trials in Inflammatory Bowel Disease were Underpowered Because of Overestimated Drug Efficacy Rates: Results from a Systematic Review of Induction Studies
Paul Bahnam, Jurij Hanzel, Christopher Ma, Lily Zou, Neeraj Narula, Siddharth Singh, Brennan Kahan, Vipul Jairath
doi : 10.1093/ecco-jcc/jjac150
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 404–417
Most pharmaceutical clinical trials for inflammatory bowel disease [IBD] are placebo-controlled and require effect size estimation for a drug relative to placebo. We compared expected effect sizes in sample size calculations [SSCs] to actual effect sizes in IBD clinical trials.
Mucosal and Plasma Metabolomes in New-onset Paediatric Inflammatory Bowel Disease: Correlations with Disease Characteristics and Plasma Inflammation Protein Markers
Niklas Nyström, Stefanie Prast-Nielsen, Mario Correia, Daniel Globisch, Lars Engstrand, Ina Schuppe-Koistinen, Jonas Halfvarson
doi : 10.1093/ecco-jcc/jjac149
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 418–432
To advance the understanding of inflammatory bowel disease [IBD] pathophysiology, we compared the mucosal and plasma metabolomes between new-onset paediatric IBD patients and symptomatic non-IBD controls, and correlated plasma inflammation markers and disease characteristics with the altered metabolites.
Autophagy Reduces the Degradation and Promotes Membrane Localization of Occludin to Enhance the Intestinal Epithelial Tight Junction Barrier against Paracellular Macromolecule Flux
Kushal Saha, Ashwinkumar Subramenium Ganapathy, Alexandra Wang, Nathan Michael Morris, Eric Suchanec, Wei Ding, Gregory Yochum, Walter Koltun, Meghali Nighot, Thomas Ma, Prashant Nighot
doi : 10.1093/ecco-jcc/jjac148
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 433–449
Functional loss of the gut epithelium’s paracellular tight junction [TJ] barrier and defective autophagy are factors potentiating inflammatory bowel disease [IBD]. Previously, we showed the role of autophagy in enhancing the intestinal TJ barrier via pore-forming claudin-2 degradation.
NOD2 in Crohn’s Disease—Unfinished Business
James J Ashton, Eleanor G Seaby, R Mark Beattie, Sarah Ennis
doi : 10.1093/ecco-jcc/jjac124
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 450–458
Studies of Crohn’s disease have consistently implicated NOD2 as the most important gene in disease pathogenesis since first being identified in 2001.
Beyond the White Pill: Advocating for Racial Diversity in IBD Trials
Emily C L Wong, Paul Moayyedi, Neeraj Narula
doi : 10.1093/ecco-jcc/jjac134
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Pages 459–461
Although inflammatory bowel disease [IBD] affects an increasingly diverse patient population, most patients in IBD clinical trials are White. Acknowledging current barriers and taking meaningful action is required at multiple levels to improve racial diversity across clinical trials in IBD. Ultimately
Erratum to: Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme
doi : 10.1093/ecco-jcc/jjac180
Journal of Crohn's and Colitis, Volume 17, Issue 3, March 2023, Page 462
